Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONCY Oncolytics Biotech Inc

Closed Good Friday 04-17 16:00:00 EDT

0.5610

-0.0070

-1.23%

盘后0.5500

-0.0110-1.96%

19:38 EDT

High0.5680	Low0.5466	Vol214.46K
Open0.5588	D1 Closing0.5680	Amplitude3.77%
Mkt Cap48.58M	Tradable Cap46.87M	Total Shares86.60M
T/O118.44K	T/O Rate0.26%	Tradable Shares83.55M
P/B11.24	ROE-189.05%	EPS-0.29
52wk High1.53	52wk Low0.4679	P/E-1.95
Dividend0.00	Div.Yield0.00	ROA-74.11%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ONCY","market":"US","secType":"STK","nameCN":"Oncolytics Biotech Inc","latestPrice":0.561,"timestamp":1744920000000,"preClose":0.568,"halted":0,"volume":214464,"hourTrading":{"tag":"盘后","latestPrice":0.55,"preClose":0.561,"latestTime":"19:38 EDT","volume":1501,"amount":825.561,"timestamp":1744933135748},"delay":0,"floatShares":83548724,"shares":86600868,"eps":-0.28815,"marketStatus":"Closed Good Friday","change":-0.007,"latestTime":"04-17 16:00:00 EDT","open":0.5588,"high":0.568,"low":0.5466,"amount":118441.527636,"amplitude":0.037676,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.28815,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1002254400000,"exchange":"NASDAQ","adjPreClose":0.568,"preHourTrading":{"tag":"盘前","latestPrice":0.568,"preClose":0.568,"latestTime":"08:22 EDT","volume":5694,"amount":2682.7070322,"timestamp":1744892554565},"postHourTrading":{"tag":"盘后","latestPrice":0.55,"preClose":0.561,"latestTime":"19:38 EDT","volume":1501,"amount":825.561,"timestamp":1744933135748},"volumeRatio":0.34823646872429037},"requestUrl":"/m/hq/s/ONCY","defaultTab":"news","newsList":[{"id":"2526346528","title":"Press Release: Oncolytics Biotech(R) Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2526346528","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526346528?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 06:09","pubTimestamp":1744322940,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital. The common shares under the SPA will be offered and sold to Alumni and may be reoffered and resold by Alumni to the public pursuant to a short form base shelf prospectus  as accompanied by a prospectus supplement  and pursuant to a prospectus supplement to a base shelf prospectus forming part of the Company's registration statement on Form F-10  registering the common shares under the United States Securities Act of 1933, as amended, pursuant to the Multi-Jurisdictional Disclosure System adopted by the United States and Canada. The final prospectus supplement has been filed with the securities commissions and other similar regulatory authorities in the province of Alberta and the United States. There will not be any sale of common shares in any province, st","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","ONCY","BK4022","R","BK4139"],"gpt_icon":0},{"id":"2526551025","title":"Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2526551025","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526551025?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 19:00","pubTimestamp":1744282800,"startTime":"0","endTime":"0","summary":"SAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ --Oncolytics BiotechInc.  , a leading clinical-stage company specializing in immunotherapy for oncology,was discussed by field-leading key opinion leaders  during a recent event hosted by H.C. Wainwright.Martine Piccart, M.D., Ph.D., an Honorary Professor of Oncology at the Université Libre de Bruxelles  and Scientific Director of Oncology at the Institut Jules Bordet, in Brussels, Belgium, offered a detailed overview of the HR+/HER2- metastatic breast cancer landscape and emphasized the need for new treatment innovations, such as pelareorep, that work to activate the immune system to recognize and kill cancer.Alexander Eggermont, M.D., Ph.D., Professor of Clinical & Translational Immunotherapy at the University Medical Center Utrecht in the Netherlands and Board Member of the Comprehensive Cancer Center Munich of the Technical University Munich and the Ludwig Maximilians University, Munich, Germany, provided insights on the curren","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oncolytics-biotech-pelareorep-discussed-during-110000298.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-pelareorep-discussed-during-110000298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2518203729","title":"Oncolytics Biotech Price Target Maintained With a $5.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2518203729","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518203729?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 01:40","pubTimestamp":1741628400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ONCY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 13:40 ET (17:40 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY"],"gpt_icon":0},{"id":"2518083952","title":"Oncolytics Biotech Is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2518083952","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518083952?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 00:53","pubTimestamp":1741625580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ONCY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 12:53 ET (16:53 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY"],"gpt_icon":0},{"id":"2518242452","title":"Analysts’ Top Healthcare Picks: Trevi Therapeutics (TRVI), Oncolytics Biotech (ONCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518242452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518242452?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 21:30","pubTimestamp":1741613428,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Trevi Therapeutics (TRVI – Research Report), Oncolyt...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-trevi-therapeutics-trvi-oncolytics-biotech-oncy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-trevi-therapeutics-trvi-oncolytics-biotech-oncy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY","BK4137","BK4139","TRVI","BK4007","HCSG"],"gpt_icon":0},{"id":"2518247781","title":"RBC Lowers Price Target on Oncolytics Biotech to CA$5 From CA$6, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2518247781","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518247781?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 19:37","pubTimestamp":1741606654,"startTime":"0","endTime":"0","summary":"RBC Lowers Price Target on Oncolytics Biotech to CA$5 From CA$6, Keeps Outperform, Speculative Risk","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ONCY","CA"],"gpt_icon":0},{"id":"2518477007","title":"Oncolytics Biotech’s Financial Stability at Risk: Urgent Need for New Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2518477007","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518477007?lang=en_us&edition=full_marsco","pubTime":"2025-03-09 14:02","pubTimestamp":1741500133,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech (ONCY) has disclosed a new risk, in the Corporate Activity and Growth category. Oncolytics Biotech faces significant business ri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oncolytics-biotechs-financial-stability-at-risk-urgent-need-for-new-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oncolytics-biotechs-financial-stability-at-risk-urgent-need-for-new-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2517419444","title":"Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2517419444","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517419444?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 15:03","pubTimestamp":1741417407,"startTime":"0","endTime":"0","summary":"Cash and Cash Equivalents: $15.9 million as of December 31, 2024.Net Cash Used in Operating Activities: $27 million for 2024, compared to $28.4 million for 2023.General and Administrative Expenses: $3.9 million for Q4 2024, down from $4.2 million in Q4 2023.Research and Development Expenses: $4.6 million for Q4 2024, compared to $4.7 million in Q4 2023.Net Loss: $8 million for Q4 2024, compared to $3.9 million for Q4 2023.Loss Per Share: $0.10 for Q4 2024, compared to $0.05 for Q4 2023.Full-Year Net Loss: $31.7 million for 2024, compared to $27.8 million in 2023.GuruFocus has detected 2 Warning Signs with ONCY.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Oncolytics Biotech Inc  reported outstanding final data in the BRACELET-1 breast cancer study, exceeding expectations.The company is planning a large Phase 2 study for HR-positive/HER2-negative breast cancer, aiming for accelerated approval.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-inc-oncy-q4-070327613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONCY"],"gpt_icon":0},{"id":"2517438534","title":"Oncolytics Q4 Net Loss Doubles, Provides Pelareorep Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438534","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438534?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 20:40","pubTimestamp":1741351248,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech  on Friday said its fourth-quarter net loss doubled as the company advances towards registrational studies for its lead candidate pelareorep. A registration enabling trial is intended to generate sufficient data to file for a marketing application.The net loss for the fourth quarter was $8.0 million, or $0.10 per share, compared with a loss of $3.9 million, or $0.05 per share, in the prior year period.As at Dec. 31, Oncolytics reported $15.9 million in cash, giving it a projected cash runway through key milestones and into the third quarter of 2025.Oncolytics is finalizing details for a large phase 2 study involving pelareorep in HR+/HER2- metastatic breast cancer, and expects a progression-free survival  readout two years after enrollment begins.The final BRACELET-1 data showed robust improvements for patients receiving pelareorep and paclitaxel compared to paclitaxel monotherapy in terms of PFS, Oncolytics said. If a PFS benefit comparable to the results seen in BR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-q4-net-loss-doubles-124048076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4195","PFS","BK4211","ONCY","BK4139"],"gpt_icon":0},{"id":"2517948457","title":"Oncolytics reports Q4 EPS (10c) vs. (5c) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2517948457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517948457?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 20:07","pubTimestamp":1741349265,"startTime":"0","endTime":"0","summary":"“With multiple clinical trials surpassing expectations in 2024, 2025 is shaping up to be a defining year for Oncolytics (ONCY). Our top priority is...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-reports-q4-eps-10c-vs-5c-last-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-reports-q4-eps-10c-vs-5c-last-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2517481107","title":"Oncolytics Biotech FY 2024 GAAP EPS C$(0.41) Beats C$(0.42) Estimate, Cash Position Of $15.9M Provides Runway Into Third Quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2517481107","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517481107?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 20:02","pubTimestamp":1741348961,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.42) by 2.38 percent. This is unchanged from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44187549/oncolytics-biotech-fy-2024-gaap-eps-c-0-41-beats-c-0-42-estimate-cash-position-of-15-9m-provides-ru","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Oncolytics Biotech FY 2024 GAAP EPS C$(0.41) Beats C$(0.42) Estimate, Cash Position Of $15.9M Provides Runway Into Third Quarter 2025","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY"],"gpt_icon":0},{"id":"2517919484","title":"Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2517919484","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517919484?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study. Promising Data in Anal Cancer with 33% Response Rate, Including a Durable 15+ Month Complete Response: In the ongoing GOBLET study, Oncolytics' pelareorep combination therapy achieved a 33% objective response rate , including a complete response lasting over 15 months, in twelve evaluable patients with second-line or later unresectable squamous cell carcinoma of the anal canal treated with pelareorep and atezolizumab . This encouraging signal in a very tough-to-treat disease further supports pelareorep's potential in solid tumors. The success criteria in Stage 1 of this Simon two-stage design were previously met; enrollment into Stage 2 of this cohort has begun and will add 18 additional","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oncolytics-biotech-reports-highlights-financial-120000587.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-reports-highlights-financial-120000587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ORR","BK4195","BK4097","ONCY","OS","BK4211","PFS"],"gpt_icon":0},{"id":"2517481546","title":"Press Release: Oncolytics Biotech(R) Reports Highlights and Financial Results for Q4 and Year-End 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2517481546","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517481546?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study. Data from GOBLET in pancreatic and anal carcinoma support continued development of pelareorep in these indications, with combination studies ongoing. SAN DIEGO and CALGARY, AB, March 7, 2025 /PRNewswire/ -- Oncolytics Biotech  Inc.  , a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for Q4 and year-end 2024. With its lead candidate, pelareorep, demonstrating strong efficacy signals in breast, pancreatic, and anal cancer, the company is strategically advancing toward registrational studies that could redefine treatment landscapes in multiple high-need indications. All dollar amounts are expressed in Canadian currency unless otherwise noted.GOBLET gastrointestinal cancer data continue to demonstrate pelareorep's potential across multiple indications. Oncolytics presented t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","ONCY","BK4097","BK4232","BK4022","ORR","R","OS","PFS","BK4195","BK4139"],"gpt_icon":0},{"id":"2517969949","title":"Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner","url":"https://stock-news.laohu8.com/highlight/detail?id=2517969949","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517969949?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 22:35","pubTimestamp":1741185306,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc.  has been beaten down lately with too much selling pressure. While the stock has lost 9.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index , one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.The heavy selling of ONCY shares appears to be in the process of exhausting itself, as indicated by its RSI reading of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-oncy-loses-9-143506990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONCY","BK4150","BK4139","RSI"],"gpt_icon":0},{"id":"2517921914","title":"Oncolytics Biotech Inc  expected to post a loss of 12 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2517921914","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517921914?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 21:34","pubTimestamp":1741181680,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc  expected to post a loss of12cents a share - Earnings Preview Oncolytics Biotech Inc ONC.TO  is expected to show no change in quarterly revenue when it reports  results on March","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL5N3PO1AB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY"],"gpt_icon":0},{"id":"2514737093","title":"Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2514737093","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514737093?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 20:00","pubTimestamp":1740484800,"startTime":"0","endTime":"0","summary":"Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET. SAN DIEGO and CALGARY, AB, Feb. 25, 2025 /PRNewswire/ -- Oncolytics BiotechInc.  , a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2024.A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clickinghere, and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing  660-6345  or  819-1450  and using replay code: 48422#.Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oncolytics-biotech-host-conference-call-120000672.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-host-conference-call-120000672.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONCY","BK4218","BK4139","HST","BK4585","BK4181","BK4588"],"gpt_icon":0},{"id":"2512197973","title":"Oncolytics provides progress update for pelareorep in pancreatic and anal cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2512197973","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512197973?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 05:16","pubTimestamp":1739913393,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) reported on progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep’s potential in hard-to-treat c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-provides-progress-update-for-pelareorep-in-pancreatic-and-anal-cancer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-provides-progress-update-for-pelareorep-in-pancreatic-and-anal-cancer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2512150334","title":"Oncolytics Biotech Receives German Clearance for Pancreatic Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2512150334","media":"MT Newswires","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512150334?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 20:59","pubTimestamp":1739883576,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech , down 4.6% in U.S. pre-market trading, on Tuesday said it has obtained safety and regulatory clearance in Germany for pelareorep to advance enrollment in its pancreatic cancer study. Thirty patients are set to participate in Stage 1 across the two treatment arms.Oncolytics also said it presented new efficacy and safety data at the 2025 American Society of Clinical Oncology  Gastrointestinal Cancers Symposium in late January.\"We're hitting critical milestones that validate our progress and set the stage for what we believe will be an exciting year,\" said Wayne Pisano, interim chief executive and the board chair. \"With positive feedback from regulators in place, we're advancing our pancreatic cancer study toward full enrollment, and our ASCO GI presentations highlighted pelareorep's strong safety and efficacy results in two hard-to-treat cancers. We remain focused on bringing new treatment options to patients while creating value for shareholders as we move forward in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-receives-german-clearance-125936134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2512197636","title":"Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2512197636","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512197636?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 20:00","pubTimestamp":1739880000,"startTime":"0","endTime":"0","summary":"Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential ofpelareorep across very different tumor types. \"We're hitting critical milestones that validate our progress and set the stage for what we believe will be an exciting year,\" said Wayne Pisano, Interim CEO and Chair of Oncolytics' Board of Directors. \"With positive feedback from regulators in place, we're advancing our pancreatic cancer study toward full enrollment, and our ASCO GI presentations highlighted pelareorep's strong safety and efficacy results in two hard-to-treat cancers. We remain focused on bringing new treatment options to patients while creating value for shareholders as we move forward in 2025.\". German Regulatory Agency Gives Green Light for Pancreatic Cancer Study to Continue as Planned. Approval to Fully Enroll the Cohort Secured: Germany's Paul-Ehrlich-Institute  has given Oncolytics the go-ahead to continue enro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oncolytics-biotech-strengthens-pipeline-2025-120000696.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-strengthens-pipeline-2025-120000696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ORR","ONCY","AIO"],"gpt_icon":0},{"id":"2511643686","title":"Oncolytics receives noncompliance notification from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2511643686","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511643686?lang=en_us&edition=full_marsco","pubTime":"2025-02-15 06:20","pubTimestamp":1739571635,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) announced that it received a delinquency notification letter from Nasdaq indicating that the company is not currently in complian...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-receives-noncompliance-notification-from-nasdaq?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-receives-noncompliance-notification-from-nasdaq?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIW.SI","TQQQ","BK4139","BK4588","QLD","NDAQ","QID","IE00BKPKM429.USD","BK4585","SQQQ","ONCY","IE00B64PRP62.GBP","USAW.SI","USJW.SI","PSQ","LU2210150020.SGD","TSYW.SI","IE00B3QW5Z07.USD","NQmain","IE00BGHQF748.EUR",".IXIC","LU2095319765.USD","MNQmain","BK4112","LU2210149790.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oncolyticsbiotech.com","stockEarnings":[{"period":"1week","weight":0.1218},{"period":"1month","weight":-0.0753},{"period":"3month","weight":-0.2908},{"period":"6month","weight":-0.5844},{"period":"1year","weight":-0.4606},{"period":"ytd","weight":-0.3861}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":-0.015183},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.050372},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.105719},{"month":4,"riseRate":0.714286,"avgChangeRate":0.020322},{"month":5,"riseRate":0.333333,"avgChangeRate":0.056551},{"month":6,"riseRate":0.166667,"avgChangeRate":0.01008},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.034622},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.108407},{"month":9,"riseRate":0,"avgChangeRate":-0.07814},{"month":10,"riseRate":0.571429,"avgChangeRate":0.186587},{"month":11,"riseRate":0.285714,"avgChangeRate":0.046234},{"month":12,"riseRate":0.142857,"avgChangeRate":0.32678}],"exchange":"NASDAQ","name":"Oncolytics Biotech Inc","nameEN":"Oncolytics Biotech Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oncolytics Biotech Inc,ONCY,Oncolytics Biotech Inc股票,Oncolytics Biotech Inc股票老虎,Oncolytics Biotech Inc股票老虎国际,Oncolytics Biotech Inc行情,Oncolytics Biotech Inc股票行情,Oncolytics Biotech Inc股价,Oncolytics Biotech Inc股市,Oncolytics Biotech Inc股票价格,Oncolytics Biotech Inc股票交易,Oncolytics Biotech Inc股票购买,Oncolytics Biotech Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction